There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerecor Inc (CERC), BioLife Solutions (BLFS) and Crispr Therapeutics AG (CRSP) with bullish sentiments.
Cerecor Inc (CERC)
In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Cerecor Inc, with a price target of $9. The company’s shares opened today at $5.20.
Higgins commented:
“We continue to look for swift development of these assets via the 505(b)(2) regulatory path, as all three were previously approved as excipients (but not active ingredients) and are supported by peer-reviewed, positive results from investigator-sponsored trials. This strategy has succeeded in several similar cases (Exhibit 1). Cerecor also completed pre-IND meetings for these compounds in mid-2018 and received Designation, making them eligible for priority review vouchers (PRVs) upon approval, which could be worth ~$105M each, based on the five most recent PRV transactions. We believe Cerecor will only need to conduct small 3 trials before NDA filings, leading to potential approvals in 2021 and 2022.”
According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.2% and a 30.7% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Paratek Pharmaceuticals, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cerecor Inc with a $9 average price target.
See today’s analyst top recommended stocks >>
BioLife Solutions (BLFS)
Northland Securities analyst Suraj Kalia maintained a Buy rating on BioLife Solutions today and set a price target of $18. The company’s shares opened today at $12.15.
Kalia said:
“We highlight underneath our understanding of the implications of this new guidance. The statement indicates an increased pace of the tune of 200/ yr. This is approx. double of current levels.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.6% and a 55.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioLife Solutions with a $20.50 average price target.
Crispr Therapeutics AG (CRSP)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG. The company’s shares opened today at $33.96.
Amusa wrote:
“We note these changes are coming as the CRISPR companies transition from preclinical-stage biotech engines to more- focused clinical-stage companies. As each company’s programs near first-in-human treatment, we look to see whether this trend stabilizes in 2019, as a signal of the overall prospects for the space.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.4% and a 46.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Logicbio Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $52.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
